The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Share News (LID)

  • There is currently no data for LID

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Anglo American Sparkles On De Beers Sales

Tue, 12th Apr 2016 09:19

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.
----------
FTSE 100 - WINNERS
----------
Anglo American, up 6.0%. The miner said rough diamond sales for its De Beers unit rose in the third sales cycle against the second. Anglo said the value of rough diamond sales by De Beers in the third sales cycle hit USD660.0 million, up from USD617.0 million in the second sales cycle for 2016. Anglo American said continued stability for polished diamond prices has supported a "reasonably positive environment" for rough diamond sales thus far in 2016.
----------
FTSE 100 - LOSERS
----------
Ashtead Group, down 3.6%. The equipment rental firm was downgraded by HSBC to Hold from Buy.

Whitbread, down 2.1%. The hotel, coffee shop and restaurant operator said Christopher Rogers, the managing director of the Costa coffee shop business, has stepped down from his post to be replaced by Dominic Paul. Rogers will step down from the board on April 20 but remain with the company until July 1 to ensure a smooth handover. Paul will take up his new role on June 6. Paul joins Whitbread from cruise company Royal Caribbean International, where he has been senior vice president of international since 2013.

AstraZeneca, down 1.0%. The drug company was cut to Sell from Neutral by Goldman Sachs.
----------
FTSE 250 - WINNERS
----------
Galliford Try, up 3.1%. The construction and housebuilding group said it is completing remedial work to remedy defects in four schools in Edinburgh, after one of the schools lost part of an external wall during a storm earlier this year. This comes after seventeen schools in Edinburgh were unable to open after the Easter break due to fears for pupil safety.
----------
FTSE 250 - LOSERS
----------
Vesuvius, down 5.7%. The molten metal flow engineering company was cut to Underperform from Hold by Jefferies.

Ted Baker, down 2.0% at 2,583.10 pence. Panmure Gordon initiated coverage on the fashion retailer with a Sell rating and 1,902 pence price target. "Several highly-rated consumer stocks have capitulated over the last quarter, reporting weak like-for-like sales growth over the comparative period. We think Ted Baker will be the next," the broker said.
----------
MAIN MARKET AND AIM - WINNERS
----------
Ferrum Crescent, up 102%. The miner said due diligence has been completed on GoldQuest Iberica and on its lead-zinc projects in Spain and said it will now be focused on securing the necessary funding to exercise its option to buy GoldQuest. Ferrum holds an exclusive option to acquire 100% of GoldQuest and has until the end of July to exercise that option. Ferrum said due diligence has been completed on the Toral and Lago lead-zinc projects that GoldQuest owns in Spain. A geological assessment indicated major potential for re-interpretation of historical data on the prospects, Ferrum said.

Altona Energy, up 15%. The coal-to-chemicals developer said shareholders in Sino-Aus Energy Group Ltd have paid the majority of the first financial contribution to the Arckaringa joint venture. Sino-Aus has made a AUD4.0 million payment, with the other AUD1.4 million expected by the end of April once approval for the transfer is secured from the Chinese government. Altona and Sino-Aus are working together on the Arckaringa coal project in Australia.

Cap-XX, up 13%. The supercapacitors company said its licence deal with Japanese electronic components maker Murata Manufacturing Co has been widened to include battery markets. CAP-XX said, at the request of Murata, it has agreed to extend the scope of the licence to allow Murata to manufacture and sell lithium ion batteries using CAP-XX patents. CAP-XX said it expects the expansion of the deal to drive a material rise in licensing revenue in coming years.
----------
MAIN MARKET AND AIM - LOSERS
----------
LiDCO Group, down 13%. The hemodynamic monitoring equipment supplier reported a swing to a pretax loss for its most recent financial year as a number of sales slipped into its current year, and it said it has renewed its distribution contract with Argon Medical Devices Inc for a further five years. For the year to end-January LiDCO reported a pretax loss of GBP578,000, swung from a pretax profit of GBP238,000 a year before, as revenue fell to GBP7.6 million from GBP8.3 million. LiDCO attributed the fall in revenue to a lower number of monitors sold and placed with hospitals.

Falkland Islands Holdings, down 10%. The UK and Falklands logistics and storage services company said its profit for the financial year to the end of March will fall due to the reduced contribution from its Momart UK art storage business. The company said its underlying profit for the year to March 31 is set to fall around by 10% to 15% year-on-year to around GBP3.0 million to GBP3.2 million. The main driver of this will be Momart, where profitability improved in the second half but will be depressed for the full year by significant investments made in marketing and sales infrastructure, along with a competitive and slowing global art market.

Deltex Medical Group, down 9.5%. The oesophageal Doppler developer said its pretax loss widened in 2015 as it continues to increase its operations, while revenue dipped slightly due to a tough UK market. Deltex said its pretax loss for the year to the end of December was GBP3.6 million, compared to a GBP3.1 million loss a year earlier as it made further investments in the business, causing gross margin to decline to 63% from 70%. This was exacerbated by revenue falling slightly to GBP6.4 million from GBP6.5 million, primarily down to a fall in probe sales in the UK caused by squeezed budgets across the National Health Service.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
6 Jun 2014 05:24

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar
Friday, June 6
Read more
5 Jun 2014 15:08

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar
Friday, June 6
Read more
5 Jun 2014 05:10

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar
Thursday, June 5
Read more
4 Jun 2014 15:29

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar
Thursday, June 5
Read more
21 May 2014 12:55

NantHealth completes communications link with LiDCO

AIM-listed medical group LiDCO announced US-based healthcare firm NantHealth has developed a communications link between LiDCO's blood analysis monitors and its DeviceConX system. NantHealth's software, DeviceConx, collects and transmits data from medical devices into an electronic record for docto

Read more
21 May 2014 11:48

LiDCO Group Monitors Link With NantHealth's Software System

LONDON (Alliance News) - LiDCO Group PLC said Wednesday said US-based NantHealth has successfully completed development of a proprietary communications link between LiDCO monitors and its own DeviceConX system. NantHealth's DeviceConX is a software solution that collects and transmits data

Read more
20 May 2014 14:56

LiDCO Says Results Of Study Using Its Cardiac Monitor Published

LONDON (Alliance News) - LiDCO Group PLC Tuesday said a recent study published in the Journal of American Medical Association found that perioperative hemodynamic intervention is associated with a reduced complication rate and length of stay in hospital after surgery. A test was conducted i

Read more
1 May 2014 10:53

LiDCO Says Study Supports Its Monitors For Post Surgery Programmes

LONDON (Alliance News) - LiDCO Group PLC Thursday noted a study that it said showed that an enhanced recovery after surgery programme using its haemodynamic monitors reduced length of hospital stay and incidences of urinary tract infections. The study, by the Enhanced Recovery Study Group a

Read more
29 Apr 2014 12:40

LiDCO Swings To Profit As Revenue Boosted By Strong UK Performance

LONDON (Alliance News) - LiDCO PLC Tuesday expressed confidence for 2014 after it swung to a pretax profit for 2013, as revenue was boosted by strong growth from its UK business. LiDCO produces cardiac monitoring equipment and disposables. LiDCO posted a pretax profit of GBP217,000, s

Read more
17 Mar 2014 13:11

LiDCO To Launch New Version Of LiDCOrapid Software

LONDON (Alliance News) - LiDCO Group PLC said Monday that it will be launching a new version of its LiDCOrapidv2 software at the International Symposium on Intensive Care and Emergency Medicine in Brussels. The conference, organised by the department of Intensive Care Emergency Medicine of

Read more
17 Mar 2014 12:49

CORRECT: UK MIDDAY BRIEFING: Housebuilders Lead FTSE 350 On More Help-To-Buy

(Correcting direction of FTSE 250 index.) LONDON (Alliance News) - Housebuilders lead a surprisingly upbeat UK equities market Monday, occupying six of the top ten spaces in the FTSE 350, buoyed by an extension to the UK government's Help to Buy scheme.

Chancellor George Osbor

Read more
17 Mar 2014 12:45

UK MIDDAY BRIEFING: Housebuilders Lead FTSE 350 On More Help-To-Buy

LONDON (Alliance News) - Housebuilders lead a surprisingly upbeat UK equities market Monday, occupying six of the top ten spaces in the FTSE 350, buoyed by an extension to the UK government's Help to Buy scheme.

Chancellor George Osborne confirmed that the government's flagship Help

Read more
17 Mar 2014 11:57

UK WINNERS & LOSERS: Housebuilders Jump; Supermarkets Fall Again

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.

-------

FTSE 100 - WINNERS

Persimmon, up 4.7%. The housebuilder's share price has jumped following c

Read more
12 Mar 2014 15:45

Medical research boosts LiDCO hopes

An independent medical study proving the cost-effectiveness of monitoring bloodflow during surgery has been welcomed by AIM-listed LiDCO, whose equipment was used for the trials. Published data examining the cost effectiveness of post-operative goal-directed therapy (GDT), a surgical intervention t

Read more
12 Mar 2014 10:17

Study Supports LiDCO's Monitoring Equipment For Postoperative Therapy

LONDON (Alliance News) - LiDCO Group PLC said Wednesday that a study into the cost-effectiveness of Postoperative Goal-Directed Therapy proved that this type of care was both cost and clinically effective, supporting the use of its LiDCOplus monitoring equipment. The LiDCOplus monitor provi

Read more

Quickpicks are a member only feature

Login to your account